From the field
Shorter, more immediate observations from conferences, market moments, conversations, and signals worth naming.
France isn't arguing about whether precision diagnostics matter anymore. The argument now is how to make them reimbursed, routine, and equitable — and that turns out to be a business-model question as much as a clinical one.
Read note →I left Roche Diagnostics Day with one overriding impression: this was not really a product launch event as much as a full diagnostics platform buildout. Roche is assembling the operating system for precision medicine.
Read note →AI is becoming unavoidable, and diagnostics is having a moment — not in the frothy, hand-wavy sense, but the industry is beginning to recognize that diagnostics are not just a support function for therapeutics. They are increasingly becoming the operating layer for precision medicine.
Read note →The UK has the NHS, Genomics England, UK Biobank, strong academic centers, and a policy narrative built around prevention and earlier detection. In other words, it has the raw materials for a precision medicine operating system. The question is whether it can turn those assets into a scalable model for adoption, reimbursement, and patient impact.
Read note →For three years, specialty diagnostics was in market purgatory — paying for its COVID-era sugar high with reimbursement skepticism, compressed valuations, and investor fatigue. The Caris IPO is a signal that the market may finally be distinguishing between diagnostics as science projects and diagnostics as scaled clinical infrastructure.
Read note →For years, the running joke in diagnostics was that specialty Dx companies could do almost everything except make money. GeneDx is showing what happens when the answer gets bigger, the clinical value gets clearer, and reimbursement starts to catch up.
Read note →